Has Puneet Khanna, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,012,556 in general payments to Puneet Khanna, MD across 395 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Puneet Khanna, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Puneet Khanna, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Puneet Khanna, MD

Interventional Cardiology · Rancho Mirage, CANPI 1053372466

Payments from drug & device makers

What this record shows

This record is dominated by other: $799,826 of the $1,012,556 with a category attached, or 79.0%. Bard Peripheral Vascular, Inc. accounts for 79.0% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2021 at $796,563 and has fallen 94.5% since, to $43,775 in 2025. Among interventional cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,012,556in general payments, 2019–2025

Across 395 payments — averaging $2563.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Bard Peripheral Vascular, Inc.$800K
Medtronic$113K
Edwards Lifesciences$96K
Abiomed$953
Cardiovascular Systems Inc.$802
Abbott$346
plus $1K from 13 others

$178,871in ownership & investment interests, 2019–2025

Across 4 payments — averaging $44,718 each. An ownership or investment interest held by the physician or an immediate family member.

Corvista Health, Inc.$179K
Vantis Vascular, Inc.$0

What the payments were for

Royalty or licence$113,20411%
Consulting fees$82,1458%
Travel & lodging$3,3810%
Food & beverage$13,8641%
Entertainment$1360%
Other$799,82679%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Bard Peripheral Vascular, Inc.	3	$799,846
Medtronic(2 entities)	4	$113,400
Edwards Lifesciences	294	$96,172
Abiomed	18	$953
Cardiovascular Systems Inc.	31	$802
Abbott	15	$346
Philips North America LLC	9	$306
Teleflex LLC	1	$137
Opsens Inc.	1	$136
Siemens Medical Solutions USA, Inc.	1	$76
Shockwave Medical, Inc	3	$73
Inari Medical, Inc.	3	$69
E.r. Squibb & Sons, L.L.C.	2	$46
Chiesi USA, Inc.	2	$45
Teleflex Incorporated	1	$44
Cardiva Medical, Inc.	2	$38
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	3	$27
Cathworks, Inc.	1	$21
ZOLL Circulation Inc	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VenaSeal$113,204
Edwards SAPIEN 3 Transcatheter Heart Valve$78,886
SAPIEN 3 Ultra RESILIA$2,401
Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$1,748
Impella$273
CoreValve Evolut$150
Orsiro Mission$137
OptoWire$136
Azurion 7 M12$115

How this compares

$1,012,556 in reported general payments places this provider in the 95th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California →

Medicare billing

Part B allowed, 2024

$575,932

Medicare patients

1,555

Services billed

8,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	389	$469,579
XareltoRivaroxaban	62	$97,763
EntrestoSacubitril/Valsartan	61	$58,070
Repatha SureclickEvolocumab	30	$37,720
JardianceEmpagliflozin	30	$29,646
MultaqDronedarone Hcl	13	$11,742
Praluent PenAlirocumab	16	$8,934
Atorvastatin Calcium	413	$4,669
ClopidogrelClopidogrel Bisulfate	363	$4,639
Metoprolol Succinate	283	$3,809
Rosuvastatin Calcium	156	$3,127
Olmesartan Medoxomil	110	$2,642
Ezetimibe	63	$2,428
Losartan Potassium	186	$2,325
Carvedilol	178	$2,100

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Rancho Mirage

Matthew Pricela Jolla$2.3M
Frederick St GoarMountain View$2.2M
Saibal KarThousand Oaks$1.1M
Rahul SharmaStanford$1M
Dennis SheehanRedwood City$900K
Suhail DohadBeverly Hills$802K
Curtiss Stinisla Jolla$759K
Christian SpiesBurlingame$719K
Evan ZahnLos Angeles$632K
Mitul PatelSan Diego$602K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →